Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Gross Profit of $125.4 thousand for fiscal year 2022.
ENDONOVO THERAPEUTICS, INC. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2022 | $125.4K | +115.7% |
| 2021 | $58.1K | -42.1% |
| 2020 | $100.4K | -53.7% |
| 2019 | $216.8K | +208.2% |
| 2018 | $70.3K | +3244.4% |
| 2015 | $2.1K | -75.8% |
| 2014 | $8.7K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $693.00 | -90.0% | -98.5% |
| June 30, 2023 | $45.2K | +16828.8% | -45.9% |
| March 31, 2023 | $83.5K | +5228.1% | +1105.0% |
| September 30, 2022 | $6.9K | +47.9% | +2496.6% |
| June 30, 2022 | $267.00 | -99.1% | -83.0% |
| March 31, 2022 | $1.6K | -95.1% | -66.5% |
| September 30, 2021 | $4.7K | -88.0% | -84.3% |
| June 30, 2021 | $29.8K | -10.6% | -7.5% |
- ENDONOVO THERAPEUTICS, INC. showed an increase of +115.7% in Gross Profit compared to the prior fiscal year.
- Over the 2014–2022 period, ENDONOVO THERAPEUTICS, INC.’s gross profit has grown by 1339.8% (from $8.7 thousand to $125.4 thousand).
- The most recent figure is from ENDONOVO THERAPEUTICS, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: